15. Expansion Plan
Strategic roadmap for scaling MedMinder Pro beyond US core market via geographic reach, new segments (health systems, pharma), and B2B models. Prioritizes regulatory alignment and proven US PMF.
1. Expansion Readiness Assessment
Current Status: Pre-PMF (Months 1-6 focus). Expansion gated on US retention >50% D30 and B2B pilot ROI proof.
| Criterion | Status | Target | Notes |
|---|
| Product-Market Fit (US) | 🟡 Pending | D30 retention >50% | Validate PDC improvement first |
| Unit Economics | 🟡 Pending | LTV:CAC >3:1 (B2B PMPM) | $2-5 PMPM pricing proven |
| Operational Processes | 🟡 Pending | HIPAA-scalable infra | API integrations stable |
| Team Capacity | 🟡 Pending | +1 FTE intl/regulatory | Outsource localization |
| Capital/Runway | 🟡 Pending | 12+ months | $750K seed covers US; $2M Series A for exp. |
Recommended Timing: Post-Month 6 (US PMF + 1st B2B pilot). Avoid distraction; leverage US playbook.
2. Geographic Expansion Strategy
Core: US (TAM $50B non-adherence savings). Prioritize English-speaking with similar chronic care models.
| Market | Language | TAM ($B) | Competition | Entry Difficulty | Priority |
|---|
| USA (Core) | English | 50 | Medium | Low (HIPAA) | Current |
| Canada | English/FR | 8 | Low | Low | 1st |
| UK/Australia | English | 12 | Low | Low | 1st |
| Germany/Netherlands | Local | 15 | Medium | Medium (GDPR) | 2nd |
| India | English | 10 | Low | Medium | 2nd |
| LATAM (Brazil/Mexico) | Local | 9 | Low | High | 3rd |
Phase 1: English-Speaking (M6-12)
- Canada/UK/AU: NHS/PBS alignment, low reg. barriers
- Investment: $10K (marketing, PHIPA/NHS compliance)
- Rev: 20% total by M12
Phase 2: Localized (M12-18)
- Germany/Netherlands: High chronic disease prevalence
- Investment: $40K (GDPR, translation)
- Rev: 15% total by M18
3. Localization Requirements
| Element | Phase 1 (En) | Phase 2 (Local) | Effort |
|---|
| UI/Content Translation | Not needed | Required | High |
| AI Interventions (Drug Names) | Minimal | Required | High |
| Date/Currency/Units | Easy | Easy | Low |
| Compliance (HIPAA→GDPR) | Standard | Full Audit | Medium |
| Market | Translation | Legal | Payment | Marketing | Total |
|---|
| Canada/UK/AU | $0 | $2K | $0 | $8K | $10K |
| Germany | $15K | $10K | $2K | $13K | $40K |
4. Market Expansion (New Segments)
Current: Adults 50+ (B2C), Care coordinators (B2B intro).
| Segment | TAM ($B) | Fit | Effort | Priority |
|---|
| Health Plans (High-risk members) | 20 | High | Medium | 1st |
| Pharmacy Chains | 15 | High | Low | 1st |
| Pharma (Specialty Drugs) | 30 | High | High | 2nd |
| Home Health Agencies | 10 | Medium | Medium | 2nd |
#1 Health Plans: $3 PMPM, pilots M9-12, $50K/mo pot.
ROI: 5x via reduced hospitalizations. GTM: RFPs, demos.
#2 Pharma: Sponsored interventions, M12+, $100K/mo pot.
Changes: Custom reports. GTM: KOL outreach.
5. Business Model Expansion
Licensing (High Viability)
Health plans/pharmacies: $2-5 PMPM. Pros: Recurring, low ops. Timeline: M9+.
White-Label (Medium)
Pharmacy apps: 40% rev share. Req: Branding API. Cons: IP risk.
API Model (High)
EHR integration: Usage-based. Req: FHIR compliance. Timeline: M12+.
6. Expansion Roadmap & Projections
12-Month Plan
M7-9: Phase 1 Geo + Health Plans- Canada/UK launch, $3 PMPM
| Timeframe | US | Phase 1 Geo | EU | B2B Segments | Total MRR |
|---|
| M6 | 85% | 10% | 0% | 5% | $15K |
| M12 | 65% | 20% | 5% | 10% | $75K |
| M18 | 50% | 20% | 10% | 20% | $250K |
7. Expansion Risks & Mitigations
| Risk | Mitigation | Severity |
|---|
| Premature Expansion | Gate on US metrics | 🔴 High |
| Intl Reg (GDPR/PIPEDA) | Pre-entry legal audit, pilots | 🟡 Medium |
| Resource Dilution | Outsource localization/support | 🟡 Medium |
| Pharma Sales Cycle | Partner-led intros | 🟡 Medium |
| Market Fit Variance | Pre-launch surveys (n=100) | 🟢 Low |
8. Expansion Success Metrics
| Metric | Definition | M12 Target |
|---|
| Non-US Revenue | % total MRR | 25% |
| New Market Payback | Inv. recovery time | <6 mo |
| Intl Retention | D30 in new mkts | >45% |
| B2B Segment Rev | % total | 15% |
| Localization ROI | Rev / Cost | 4x Y1 |
Go/No-Go: M9: Phase 1 users >200 → Proceed; else pause.